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Introduction {#s1}
============

The association between bleeding and increased morbidity and mortality after percutaneous coronary intervention (PCI) has prompted the implementation of bleeding reduction strategies at the time of PCI.^[@EHV498C1],[@EHV498C2]^ According to clinical trial data, compared with femoral access, the radial artery approach for PCI has been demonstrated to have similar efficacy with the benefit of reduced major bleeding and access site complications.^[@EHV498C3]^ Owing to a favourable safety profile, several guidelines endorse the radial artery as the preferred PCI access site.^[@EHV498C7],[@EHV498C8]^

Cangrelor is an intravenous P2Y~12~ receptor antagonist with an immediate (within 2 min) onset of action and a half-life of 3--6 min, allowing platelet function to return to baseline within 60 min of infusion cessation. In the Cangrelor vs. Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX trial, the intravenous P2Y~12~ receptor antagonist, cangrelor, reduced the rate of ischaemic events at 48 h in patients undergoing percutaneous revascularization without a significant increase in severe bleeding or transfusions.^[@EHV498C9]^ In this pre-specified secondary analysis, we explore the efficacy and safety of cangrelor according to access site (femoral vs. radial) in the CHAMPION PHOENIX trial.

Methods {#s2}
=======

Patient population {#s2a}
------------------

CHAMPION PHOENIX was a double-blind, double-dummy, placebo-controlled trial of cangrelor in patients undergoing PCI. Both the design and primary findings have been published previously.^[@EHV498C9],[@EHV498C10]^ Briefly, 11 145 patients undergoing either elective or urgent PCI and receiving guideline-recommended therapy were randomized after angiography to receive a bolus (30 µg/kg) and infusion (4 µg/kg/min for a minimum of 2 h or the duration of the procedure whichever was longer) of cangrelor or a 600 or 300 mg loading dose of clopidogrel. The timing (before or after PCI) and dose of clopidogrel were at the discretion of the site investigator. The access approach for PCI was determined by the site investigator and did not require institutional review board (IRB) approval. At the end of the infusion, patients then received either 600 mg of clopidogrel (cangrelor group) or matching placebo (clopidogrel group; *Figure [1](#EHV498F1){ref-type="fig"}*).

![Study design. SA, stable angina; NSTE-ACS, non-ST segment elevation acute coronary syndrome; STEMI, ST segment elevation myocardial infarction; PCI, percutaneous coronary intervention.](ehv49801){#EHV498F1}

Endpoints {#s2b}
---------

The primary efficacy endpoint was a composite of death (by any cause), myocardial infarction (MI), ischaemia-driven revascularization (IDR), or stent thrombosis in the first 48 h following randomization. Criteria for MI within 48 h post-PCI were defined as an elevation in creatine kinase-myocardial band (CK-MB) greater than three times the upper limit of normal or by a combination of CK-MB elevation in addition to ischaemic symptoms, angiographic evidence, and/or ECG changes. The key secondary endpoint was the incidence of stent thrombosis at 48 h, which was defined according to the Academic Research Consortium criteria or as intraprocedural stent thrombosis.^[@EHV498C11]^ All events of death, MI, IDR, and stent thrombosis were adjudicated. The primary safety endpoint was severe non-coronary artery bypass grafting (CABG) bleeding according to the Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) criteria. Thrombolysis In Myocardial Infarction (TIMI) and Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) bleeding definitions were also evaluated. Bleeding endpoints, based on pre-specified criteria, were derived from investigator-reported data using a computer algorithm. Bleeding endpoints were not adjudicated.

Statistical analysis {#s2c}
--------------------

This was a pre-specified analysis outlined in the CHAMPION PHOENIX study protocol, which was approved by local ethics committees. Independent verification of these analyses by Harvard Clinical Research Institute did not require specific IRB approval. Efficacy analyses were performed from the modified intention-to-treat (mITT) population, defined as subjects undergoing PCI and receiving study drug. Bleeding analyses were performed from the safety population, defined as subjects receiving study drug. Baseline characteristics were summarized by vascular access (femoral vs. radial) and treatment (cangrelor vs. clopidogrel); and were compared using analysis of variance for continuous variables and the *χ*^2^ test for categorical variables. Treatment comparisons within access site (cangrelor vs. clopidogrel) were not adjusted for baseline characteristics, were based on the *χ*^2^ test, and are presented as odds ratios with 95% confidence intervals (CIs). The number needed to treat (NNT) was derived within the femoral and radial subgroups as the inverse of the difference between the cangrelor and clopidogrel event rates. The interaction between treatment and PCI access site was tested using the Breslow--Day method. Time-to-event curves for the primary efficacy endpoint at 48 h were constructed using the Kaplan--Meier method and compared using the log-rank test.

Multivariable logistic regression modelling was performed using propensity scores to assess the effect of PCI access site (femoral or radial), using femoral approach as the reference, with study treatment in the model and the propensity score based on the following potential variables: diagnosis at presentation, region (US/non-US), smoking status, hyperlipidaemia, previous MI, prior PCI, prior CABG, peripheral artery disease, planned clopidogrel loading dose (300 or 600 mg), and anticoagulant (bivalirudin or heparin). Statistical analyses were conducted using the SAS software, version 9.3 (SAS Institute, Cary, North Carolina, USA).

Results {#s3}
=======

Patients {#s3a}
--------

Out of 11 145 patients randomized in CHAMPION PHOENIX, 10 942 patients comprised the mITT population who received study treatment and underwent PCI. Of these patients, 8064 (74%) underwent PCI via the femoral artery and 2855 (26%) via the radial approach. Three patients in the radial cohort did not complete the 48-h post-PCI follow-up and were excluded from the efficacy endpoint analyses; 23 patients underwent brachial PCI and were not included in this analysis.

Cangrelor vs. clopidogrel {#s3b}
-------------------------

Baseline characteristics according to access site (femoral vs. radial) and randomized treatment (cangrelor vs. clopidogrel) are depicted in *Table [1](#EHV498TB1){ref-type="table"}*. In the femoral cohort, subjects randomized to cangrelor had higher rates of peripheral artery disease (8.2 vs. 6.7%, *P* = 0.01). In the radial cohort, subjects randomized to cangrelor had a lower median weight (84 vs. 85 kg, *P* = 0.008).

###### 

Baseline characteristics

                                 Femoral            Radial                                                          
  ------------------------------ ------------------ ------------------ ------ ------------------ ------------------ -------
  Characteristic                                                                                                    
   Demographic                                                                                                      
    *n*                          4053               4011                      1410               1445               
  Age, years                                                                                                        
   Median                        64                 64                 0.51   64.5               64                 0.11
   Interquartile range           56, 72             56, 72                    57, 72             56, 71             
  Female sex, *n* (%)            1144 (28.2)        1107 (27.6)        0.53   413 (29.3)         382 (26.4)         0.09
  Weight, kg                                                                                                        
   Median                        84                 84                 0.86   84                 85                 0.008
   Interquartile range           73, 96             73, 96                    73, 95             75, 96             
  Medical history, *n* (%)                                                                                          
   Diabetes mellitus             1106/4048 (27.3)   1094/4005 (27.3)   1.00   409/1407 (29.1)    438/1444 (30.3)    0.46
   Current smoker                1142/3950 (28.9)   1148/3918 (29.3)   0.70   357/1380 (25.9)    398/1408 (28.3)    0.15
   Hypertension                  3239/4040 (80.2)   3156/3998 (78.9)   0.17   1127/1410 (79.9)   1164/1442 (80.7)   0.59
   Hyperlipidaemia               2434/3507 (69.4)   2366/3447 (68.6)   0.49   923/1336 (69.1)    963/1376 (70.0)    0.61
   Prior stroke or TIA           210/4039 (5.2)     180/3996 (4.5)     0.15   61/1407 (4.3)      61/1442 (4.2)      0.89
   Prior myocardial infarction   844/4030 (20.9)    914/3982 (23.0)    0.03   245/1402 (17.5)    258/1435 (18.0)    0.73
   Prior PTCA or PCI             913/4045 (22.6)    947/4003 (23.7)    0.25   353/1408 (25.1)    383/1444 (26.5)    0.38
   CABG                          495/4048 (12.2)    436/4006 (10.9)    0.06   81/1409 (5.7)      63/1444 (4.4)      0.09
   Heart failure                 412/4044 (10.2)    443/4002 (11.1)    0.20   137/1407 (9.7)     140/1440 (9.7)     0.99
   Peripheral artery disease     328/4015 (8.2)     268/3978 (6.7)     0.01   119/1384 (8.6)     112/1427 (7.8)     0.47

TIA, transient ischaemic attack; PTCA, percutaneous transluminal coronary angioplasty; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft.

Radial vs. femoral {#s3c}
------------------

Baseline characteristics according to access site only (femoral vs. radial) are depicted in the [Supplementary material online, *Table S1*](#sup1){ref-type="supplementary-material"}. Compared with the femoral cohort, subjects in the radial cohort had higher rates of diabetes mellitus (27.3 vs. 29.7%, *P* = 0.01) and prior PCI (23.1 vs. 25.8%, *P* = 0.004), but lower rates of current smoking (29.1 vs. 27.1%, *P* = 0.04), prior MI (21.9 vs. 17.7%, *P* \< 0.0001), and prior CABG (11.6 vs. 5.0%, *P* \< 0.0001) ([Supplementary material online, *Table S1*](#sup1){ref-type="supplementary-material"}).

Procedure characteristics {#s3d}
-------------------------

### Cangrelor vs. clopidogrel {#s3d1}

Procedure characteristics according to access site (femoral vs. radial) and randomized treatment (cangrelor vs. clopidogrel) are depicted in *Table [2](#EHV498TB2){ref-type="table"}*. In the femoral cohort, subjects randomized to cangrelor had lower rates of glycoprotein IIb/IIIa inhibitor use (2.7 vs. 4.3%, *P* = 0.0001).

###### 

Procedure characteristics

                                                Femoral            Radial                                                                     
  --------------------------------------------- ------------------ ------------------ ----------------- ------------------ ------------------ ------
  Indication, *n* (%)                                                                 0.95                                                    0.06
   Stable angina                                2290/4053 (56.5)   2258/4011 (56.3)                     888/1410 (63.0)    905/1445 (62.6)    
   NSTE-ACS                                     1099/4053 (27.1)   1085/4011 (27.1)   365/1410 (25.9)   341/1445 (23.6)                       
   STEMI                                        664/4053 (16.4)    668/4011 (16.7)    157/1410 (11.1)   199/1445 (13.8)                       
  Antithrombotic, *n* (%)                                                                                                                     
   Aspirin                                      3851/4050 (95.1)   3796/4007 (94.7)   0.47              1304/1410 (92.5)   1338/1444 (92.7)   0.86
   Clopidogrel, 300 mg loading dose (planned)   1322/4053 (32.6)   1332/4011 (33.2)   0.57              79/1410 (5.6)      62/1445 (4.3)      0.11
   Clopidogrel, 600 mg loading dose (planned)   2731/4053 (67.4)   2679/4011 (66.8)   0.57              1331/1410 (94.4)   1383/1445 (95.7)   0.11
   Low molecular weight heparin                 580/4053 (14.3)    579/4011 (14.4)    0.87              150/1410 (10.6)    174/1443 (12.1)    0.23
   Unfractionated heparin                       3045/4053 (75.1)   3020/4010 (75.3)   0.85              1220/1410 (86.5)   1243/1445 (86.0)   0.70
   Fondaparinux                                 117/4053 (2.9)     92/4011 (2.3)      0.09              39/1409 (2.8)      43/1445 (3.0)      0.74
   Bivalirudin                                  944/4053 (23.3)    940/4009 (23.4)    0.87              307/1410 (21.8)    326/1445 (22.6)    0.61
   Glycoprotein IIb/IIIa inhibitor              111/4053 (2.7)     173/4011 (4.3)     0.0001            41/1410 (2.9)      54/1445 (3.7)      0.22

NSTE-ACS, non-ST-elevation acute coronary syndrome; STE ACS, ST-elevation acute coronary syndrome; PCI, percutaneous coronary intervention.

### Femoral vs. radial {#s3d2}

Procedure characteristics according to access site only (femoral vs. radial) are depicted in the [Supplementary material online, *Table S2*](#sup1){ref-type="supplementary-material"}. Patients in the radial cohort had lower rates of aspirin (94.9 vs. 92.6%, *P* \< 0.0001) and low molecular weight heparin (14.4 vs. 11.4%, *P* \< 0.0001) use, but had higher rates of unfractionated heparin (75.2 vs. 86.3%, *P* \< 0.0001) use at the time of PCI compared with patients in the femoral cohort. The clopidogrel 600 mg loading dose was used less often in the femoral (67.1%) cohort compared with the radial (95.1%) cohort, *P* \< 0.0001. Percutaneous coronary intervention duration (17 min femoral vs. 18 min radial, *P* = 0.34) and success rate (98.2% femoral and 98.3% radial, *P* = 0.68) were similar in both groups. Of the femoral cohort, 53.5% of patients received a drug eluting stent, compared with 61.8% of patients in the radial cohort, *P* \< 0.001.

Outcomes {#s3e}
--------

### Cangrelor vs. clopidogrel {#s3e1}

In the femoral cohort, the rate of the primary efficacy endpoint of death, MI, IDR, or stent thrombosis at 48 h was 4.8% with cangrelor vs. 6.0% with clopidogrel (odds ratio \[OR\] 95% CI = 0.79 \[0.65--0.96\]), NNT 84; in the radial cohort, the primary efficacy endpoint rate was 4.4% with cangrelor vs. 5.7% with clopidogrel (OR \[95% CI\] = 0.76 \[0.54--1.06\]), *P*-interaction = 0.83; NNT 74. *Figure [2](#EHV498F2){ref-type="fig"}A* and *B* depicts the Kaplan--Meier estimates for the time-to-event for the primary endpoint in both the femoral and radial cohorts. Among the femoral cohorts, the key secondary endpoint of stent thrombosis at 48 h was 0.8% with cangrelor vs. 1.5% with clopidogrel (OR \[95% CI\] = 0.52 \[0.34--0.80\]); in the radial cohort, the rate of stent thrombosis at 48 h was 0.9% with cangrelor vs. 0.8% with clopidogrel (OR \[95% CI\] = 1.11 \[0.51--2.45\]), *P*-interaction 0.09. The effects of cangrelor on the primary and secondary endpoints in the overall study population and according to access site are shown in *Figure [3](#EHV498F3){ref-type="fig"}A*.

![(*A*) Kaplan--Meier curves for the primary efficacy endpoint in the subgroup undergoing femoral access (cangrelor vs. clopidogrel). (*B*) Kaplan--Meier curves for the primary efficacy endpoint in the subgroup undergoing radial access (cangrelor vs. clopidogrel). HR, hazard ratio; CI, confidence interval.](ehv49802){#EHV498F2}

![(*A*) Efficacy of cangrelor vs. clopidogrel in the femoral and radial subgroups. MI, myocardial infarction; IDR, ischaemia-driven revascularization; ST, stent thrombosis; OR, odds ratio; CI, confidence interval. (*B*) Bleeding with cangrelor vs. clopidogrel in the femoral and radial subgroups. GUSTO, Global Use of Strategies to Open Occluded Arteries; TIMI, Thrombolysis In Myocardial Infarction; ACUITY, Acute Catheterization and Urgent Intervention Triage strategY; OR, odds ratio; CI, confidence interval.](ehv49803){#EHV498F3}

In both access cohorts, there were no significant differences in the rates of GUSTO severe bleeding, TIMI major bleeding, or blood transfusions in patients treated with cangrelor compared with clopidogrel. In the femoral cohort, the rate of ACUITY major bleeding was 5.2% with cangrelor vs. 3.1% with clopidogrel (OR \[95% CI\] = 1.69 \[1.35--2.12), *P* \< 0.0001; in the radial cohort, the rate of ACUITY major bleeding was 1.5% with cangrelor vs. 0.7% with clopidogrel (OR \[95% CI\] = 2.17 \[1.02--4.62\]), *P* = 0.04 and *P*-interaction 0.54. The effects of cangrelor on bleeding according to access site and categorized by the various bleeding criteria are listed in *Table [3](#EHV498TB3){ref-type="table"}*. The effects of cangrelor on bleeding in the overall study population and according to access site are shown in *Figure [3](#EHV498F3){ref-type="fig"}B*.

###### 

Safety endpoints at 48 h after randomization

  Endpoint                      Femoral           Radial            *P-*interaction                                                                                  
  ----------------------------- ----------------- ----------------- -------------------- ---------- ----------------- ---------------- -------------------- -------- ------
  GUSTO bleeding                                                                                                                                                     
   Severe or life threatening   7/4052 (0.2)      4/4012 (0.1)      1.73 (0.51--5.93)    0.37       2/1411 (0.1)      2/1444 (0.1)     1.02 (0.14--7.28)    0.98     0.65
   Moderate                     20/4052 (0.5)     12/4012 (0.3)     1.65 (0.81--3.39)    0.16       2/1411 (0.1)      1/1444 (0.1)     2.05 (0.19--22.61)   0.55     0.87
   Severe/moderate              27/4052 (0.7)     16/4012 (0.4)     1.68 (0.90--3.11)    0.10       4/1411 (0.3)      3/1444 (0.2)     1.37 (0.31--6.11)    0.68     0.80
  TIMI bleeding                                                                                                                                                      
   Major                        3/4052 (0.1)      3/4012 (0.1)      0.99 (0.20--4.91)    0.99       2/1411 (0.1)      2/ 1444 (0.1)    1.02 (0.14--7.28)    0.98     0.98
   Minor                        9/4052 (0.2)      3/4012 (0.1)      2.97 (0.80--11.00)   0.09       0/1411 (0.0)      0/1444 (0.0)                                   
   Major/minor                  12/4052 (0.3)     6/4012 (0.1)      1.98 (0.74--5.29)    0.16       2/1411 (0.1)      2/1444 (0.1)     1.02 (0.14--7.28)    0.98     0.55
  ACUITY bleeding                                                                                                                                                    
   Major                        209/4052 (5.2)    125/4012 (3.1)    1.69 (1.35--2.12)    \<0.0001   21/1411 (1.5)     10/1444 (0.7)    2.17 (1.02--4.62)    0.04     0.54
   Minor                        510/4052 (12.6)   369/4012 (9.2)    1.42 (1.23--1.64)    \<0.0001   139/1411 (9.9)    94/1444 (6.5)    1.57 (1.19--2.06)    0.001    0.53
   Major/minor                  690/4052 (17.0)   483/4012 (12.0)   1.50 (1.32--1.70)    \<0.0001   158/1411 (11.2)   104/1444 (7.2)   1.62 (1.25--2.11)    0.0002   0.59
  Blood transfusion             22/4052 (0.5)     14/4012 (0.3)     1.56 (0.80--3.05)    0.19       3/1411 (0.2)      2/1444 (0.1)     1.54 (0.26--9.21)    0.63     0.99

GUSTO, Global Use of Strategies to Open Occluded Arteries; Thrombolysis In Myocardial Infarction; ACUITY, Acute Catheterization and Urgent Intervention Triage strategY; OR, odds ratio; CI, confidence interval.

### Femoral vs. radial {#s3e2}

Among patients undergoing PCI via the femoral artery, the rate of the primary efficacy endpoint at 48 h was 5.4 vs. 5.1% in the radial group (unadjusted OR 95% CI = 0.95 \[0.78--1.15\]), *P* = 0.58. After multivariable analysis, compared with patients undergoing PCI via the femoral artery, there was no difference in the adjusted rate of primary efficacy endpoint in the radial access cohort (OR \[95% CI\] = 1.03 \[0.81--1.29\]), *P* = 0.83. Efficacy endpoints (unadjusted and adjusted) according to access site are displayed in [Supplementary material online, *Table S3*](#sup1){ref-type="supplementary-material"}.

In the femoral cohort, the rate of GUSTO severe/moderate bleeding was 0.5% compared with 0.2% in the radial cohort (unadjusted OR \[95% CI\] = 0.46 \[0.21--1.02\]; *P* = 0.05). The rate of TIMI major/minor bleeding in the femoral cohort was 0.2% compared with 0.1% in the radial cohort (unadjusted OR \[95% CI\] = 0.63 \[0.21--1.85\]; *P* = 0.39). Lastly, the rate of ACUITY major/minor bleeding was 14.5% in the femoral cohort and 9.2% in the radial group (unadjusted OR \[95% CI\] = 0.60 \[0.52--0.68\]; *P* \< 0.0001). After multivariable analysis, compared with PCI via the femoral artery, using the radial approach was associated with a decreased odds of GUSTO severe/moderate (OR \[95% CI\] = 0.35 \[0.12--1.01\]; *P* = 0.05), TIMI major/minor bleeding (OR \[95% CI\] = 0.34 \[0.07--1.54\]; *P* = 0.16), and ACUITY major/minor bleeding (OR \[95% CI\] = 0.70 \[0.59--0.83\]; *P* \< 0.0001 (*Table [4](#EHV498TB4){ref-type="table"}*).

###### 

Safety endpoints at 48 h: radial vs. femoral

  Endpoint                      Femoral            Radial           OR (95% CI) unadjusted   *P*-value   OR (95% CI) adjusted   *P*-value
  ----------------------------- ------------------ ---------------- ------------------------ ----------- ---------------------- -----------
  GUSTO bleeding                                                                                                                
   Severe or life threatening   11/8064 (0.1)      4/2855 (0.1)     1.03 (0.33, 3.23)        0.96                               
   Moderate                     32/8064 (0.4)      3/2855 (0.1)     0.26 (0.08, 0.86)        0.02                               
   Severe/moderate              43/8064 (0.5)      7/2855 (0.2)     0.46 (0.21, 1.02)        0.05        0.35 (0.12--1.01)      0.05
  TIMI bleeding                                                                                                                 
   Major                        6/8064 (0.1)       4/2855 (0.1)     1.89 (0.53, 6.67)        0.32                               
   Minor                        12/8064 (0.1)      0/2855 (0.0)     --                       0.04                               
   Major/minor                  18/8064 (0.2)      4/2855 (0.1)     0.63 (0.21, 1.85)        0.39        0.34 (0.07--1.54)      0.16
  ACUITY bleeding                                                                                                               
   Major                        334/8064 (4.1)     31/2855 (1.1)    0.25 (0.18, 0.37)        \<0.0001                           
   Minor                        879/8064 (10.9)    233/2855 (8.2)   0.72 (0.63, 0.85)        \<0.0001                           
   Major/minor                  1173/8064 (14.5)   262/2855 (9.2)   0.60 (0.52, 0.68)        \<0.0001    0.70 (0.59--0.83)      \<0.0001
  All non-CABG bleeding         1173/8064 (14.5)   262/2855 (9.2)   0.60 (0.52, 0.68)        \<0.0001                           

GUSTO, Global Use of Strategies to Open Occluded Arteries; Thrombolysis In Myocardial Infarction; ACUITY, Acute Catheterization and Urgent Intervention Triage strategY; CABG, coronary artery bypass graft; OR, odds ratio; CI, confidence interval.

Discussion {#s4}
==========

Intravenous adenosine diphosphate (ADP) receptor blockade with cangrelor, when compared with clopidogrel, reduced the primary composite outcome of death, MI, IDR, or stent thrombosis at 48 h after randomization regardless of PCI access site. Among the femoral access subjects, cangrelor compared with clopidogrel reduced the odds of the primary composite outcome by 21%; within the radial cohort, there was a consistent 24% reduction in the odds of the primary composite outcome. Although the interaction tests for access site did not reach statistical significance, when the primary composite endpoint was evaluated according to access site, cangrelor demonstrated a reduction in odds of ischaemic events among patients undergoing femoral PCI. In patients undergoing PCI via the radial artery, cangrelor demonstrated a non-significant trend towards fewer ischaemic events, likely due to lack of statistical power because of a smaller sample size. In the femoral cohort, cangrelor\'s benefit with respect to ischaemic events was driven by a reduction in MI and stent thrombosis, consistent with the overall CHAMPION PHOENIX results. The radial cohort, however, only experienced a reduction in MI. The lack of benefit regarding stent thrombosis in the radial cohort is conceivably due to a low event frequency within this particular subgroup: 95 total (1.2%) in the femoral vs. 25 total (0.9%) in the radial.

In both the femoral and radial groups, cangrelor compared with clopidogrel was not associated with a significant increase in the pre-specified GUSTO-defined severe bleeding, the primary safety endpoint, or in blood transfusions; though more sensitive definitions such as ACUITY-defined bleeding did show increased rates of bleeding with cangrelor in both the femoral and radial cohorts. It is important to note that the absolute rates of GUSTO severe/moderate bleeding and blood transfusions were approximately two to three times higher with the femoral approach compared with the radial, in both the cangrelor and clopidogrel arms of the study. These findings are consistent with prior studies. The analysis of all femoral vs. radial randomized PCI clinical trials has found radial access, when compared with femoral, to be associated with a 42% reduction in non-CABG bleeding.^[@EHV498C5]^ Contemporary studies have demonstrated that up to 70% of bleeding events occurring in the PCI setting can be attributed to complications arising at the site of vascular access.^[@EHV498C12]^ The present study suggests that in a large contemporary international trial, the radial approach for PCI has the potential to play a key role in reducing periprocedural bleeding in a wide variety of PCI patients.

It is postulated that a reduction in access site bleeding may in turn lead to fewer subsequent adverse events.^[@EHV498C13]^ For example, the aforementioned 42% reduction in major non-CABG bleeding associated with the radial approach for PCI was paralleled with an aggregate reduction of major adverse cardiac events (death, MI, or stroke) of 14%, *P* = 0.005.^[@EHV498C5]^ After multivariable analysis the present study finds the odds of periprocedural bleeding 30--66% lower, depending on bleeding definition, when PCI was performed via the radial artery compared with the femoral approach. However, the favourable bleeding profile associated with the radial artery approach to PCI in CHAMPION PHOENIX did not translate into a reduction in the primary efficacy endpoint at 48 h.

There are certain limitations to this analysis. First, similar to the overall CHAMPION PHOENIX trial, there is the potential for the benefit of cangrelor to be attenuated in the setting of more prolonged pretreatment with clopidogrel or with the use or ticagrelor or prasugrel. Secondly, bleeding endpoints were not adjudicated. Thirdly, the treatment by radial vs. femoral access was not randomized and even with the adjusted analyses, there may be residual confounding. Lastly, CHAMPION PHOENIX was not powered to test the interaction between treatment and PCI access site; therefore, all interaction terms should be interpreted with caution.

In CHAMPION PHOENIX, intravenous ADP-receptor inhibition with cangrelor reduced ischaemic events with no significant increase in severe bleeding or blood transfusions regardless of PCI access site. Compared with the femoral approach, rates of bleeding complications appeared to be lower with radial access for PCI in both randomized arms of the study.
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